Form 8-K - Current report:
SEC Accession No. 0001104659-20-076844
Filing Date
2020-06-25
Accepted
2020-06-25 16:00:48
Documents
15
Period of Report
2020-06-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2023294d1_8k.htm   iXBRL 8-K 34190
2 EXHIBIT 10.1 tm2023294d1_ex10-1.htm EX-10.1 96107
3 EXHIBIT 10.2 tm2023294d1_ex10-2.htm EX-10.2 50580
4 EXHIBIT 10.3 tm2023294d1_ex10-3.htm EX-10.3 36460
  Complete submission text file 0001104659-20-076844.txt   433781

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA tbph-20200622.xsd EX-101.SCH 3192
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20200622_lab.xml EX-101.LAB 34591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20200622_pre.xml EX-101.PRE 22714
12 EXTRACTED XBRL INSTANCE DOCUMENT tm2023294d1_8k_htm.xml XML 3625
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 20989281
SIC: 2834 Pharmaceutical Preparations